Skip to main content
BIAFW logo

bioAffinity Technologies, Inc. (BIAFW) Stock Price & Analysis

bioAffinity Technologies, Inc. (BIAFW) — price $0.1506 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.1506 $0.00 (0.00%)

bioAffinity Technologies, Inc. · BIAFW

bioAffinity Technologies, Inc. is a development-stage company focused on early cancer diagnostics and targeted therapeutics. They utilize proprietary in-vitro diagnostic tests and technology that preferentially targets cancer cells.

Price as of Nov 19, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CCEL · Cryo-Cell International, Inc. · 33 /100
  • ECOR · electroCore, Inc. · 25 /100
  • NMTC · NeuroOne Medical Technologies Corporation · 22 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.1506
Change on the day0.00%
52-week range$0.0501 – $0.98
Shares traded on the day54

Price & events

Other perspectives

Council score for bioAffinity Technologies (BIAFW): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Moderate
ROE Negative
Gross Margin Weak

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is bioAffinity Technologies (BIAFW), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. bioAffinity Technologies, Inc. (BIAFW) is the company analyzed here. It employs 57 people and is led by Maria Zannes. In Q3 FY2026 it reported revenue of $1M and net income of -$5M.

2 · Latest results

What do the latest results show for bioAffinity Technologies (BIAFW)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1M-$5M-$5.89 (diluted)
Q2 FY2026$2M-$3M-$9.60 (diluted)
Q1 FY2026$1M-$4M-$12.15 (diluted)
Q4 FY2025$2M-$3M-$27.30 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for bioAffinity Technologies (BIAFW)?

Short answer · as of

The distress and quality screens read Altman Z -18.82 · Piotroski F 2. Trailing ratios: current ratio 1.51.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -18.82 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BIAFW in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BIAFW in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

bioAffinity Technologies Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the BIAFW research dossier (written Mar 18, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What does bioAffinity Technologies, Inc. do?

bioAffinity Technologies, Inc. is a development-stage company focused on developing and commercializing innovative diagnostic tests and targeted therapeutics for cancer.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.